Understand the source comparison
KPV 30s Age Specific Protocol: Comparison
Typical Dose Range 500–1,000 mcg, 3–5x/week 1,000–2,000 mcg, 5–7x/week Variable (curcumin 500–1,000 mg daily) Lower dosing in 30s reflects preventive vs corrective intent Primary Mechanism NF-κB translocation inhibition via α-MSH receptor binding Same mechanis
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Typical Dose Range
- 500–1,000 mcg, 3–5x/week
- 1,000–2,000 mcg, 5–7x/week
- Variable (curcumin 500–1,000 mg daily)
- Lower dosing in 30s reflects preventive vs corrective intent
- Primary Mechanism
- NF-κB translocation inhibition via α-MSH receptor binding
- Same mechanism, higher dose to counter established inflammation
- COX-2 inhibition (curcumin), antioxidant activity
- KPV targets upstream transcription factors; supplements target downstream mediators
- Bioavailability
- Subcutaneous: 85–95%; Intranasal: 30–50%
- Subcutaneous: 85–95%
- Curcumin: <1% without piperine enhancement
- Peptide delivery bypasses first-pass metabolism
- Onset of Subjective Effects
- 2–4 weeks (recovery improvement, reduced stiffness)
- 4–8 weeks (joint pain reduction, CRP decline)
- 4–12 weeks (variable based on formulation)
- Earlier onset in 30s reflects lower baseline inflammation
- hs-CRP Reduction (12 weeks)
- 15–30% from baseline
- 20–40% from baseline
- 10–25% (curcumin, omega-3 combined)
- KPV's NF-κB mechanism produces consistent reduction across demographics
- Professional Assessment
- KPV in the 30s targets subclinical inflammation before metabolic dysfunction becomes measurable. This is the decade where prevention compounds across lifespan. Generic supplements lack receptor specificity and require far higher doses to produce comparable anti-inflammatory effects.